For Rapid Vaccine Production … One transfection technology from concept to clinic.

.

  • Produce complex antigens, virus like particles (VLPs), and viral vectors in weeks not months
  • Produce diagnostic antibodies for your vaccine avoiding commercial limitations
  • Scale seamlessly from discovery to phase I clinical with a single technology
  • Achieve reproducibility and technology consistency avoiding time consuming re-
    optimization through each phase
  • Transient and stable cell line development strategies can be employed simultaneously
  • MaxCyte is the only electroporation platform with a clear regulatory pathway, saving more
    time as you move into the clinic.

MaxCyte’s technology was developed for the clinic.

  • High Loading Efficiency
  • High Cell Viability
  • Reproducibility
  • Technology Consistency
  • A Regulatory Pathway
  • 80+ clinical programs (maybe highlight this in some other way – see parentheses at the top)
  • In-lab scientific expertise

From R&D to Bioproduction

Production of AAV in HEK Cells



‘Proven rapid vaccine production with MaxCyte’s cell engineering transfection technology, saving many months of critical development time to get your vaccine candidate into clinical trials in record time.’

See how MaxCyte’s Expertise Working for You!